Capricor Therapeutics ($CAPR) Investors Are Notified of The Ongoing Securities Fraud Investigation After Clinical Data Issues Lead to 64% Stock Drop
Bleichmar Fonti & Auld LLP announced an investigation into Capricor Therapeutics regarding potential securities fraud tied to statements about its Deramiocel clinical data. The investigation follows a reported 64.5% stock drop on July 27, 2026, after FDA briefing documents raised concerns about post-hoc changes to the statistical analysis plan for the drug's primary endpoint.
Key figures
- New close
- $7.00
- Prior close
- $19.70
- Price decline
- $12.70
- Stock drop percent
- 64.5%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.